A simple liquid sample may eventually provide doctors with valuable information about bladder cancer. Researchers have developed an experimental testing method that examines RNA molecules released from cells, offering a way to identify signs of cancer while revealing details about its biological activity.

The research, reported in Nature Medicine in 2026, represents a different direction for liquid biopsy technology. Instead of concentrating mainly on DNA fragments circulating in blood, scientists examined RNA, a molecule that carries information about which genes are active. Samples collected from the bladder may contain molecular clues released by abnormal cells in the area.

Why Researchers Are Turning to RNA

DNA and RNA perform different but closely connected roles in cells. DNA stores genetic instructions, while RNA helps carry out those instructions by participating in protein production and regulating cellular activity. Examining RNA can therefore provide a snapshot of what is happening inside cells.

Cancer cells often behave differently from healthy cells. Their patterns of gene activity can change as tumors develop, grow or respond to treatment. Measuring RNA molecules may help researchers identify these differences and gain information that DNA-only analysis might not provide.

However, RNA presents a technical challenge. It is generally less stable than DNA and can break down quickly after leaving cells. This makes the collection, preservation and measurement of small RNA fragments particularly demanding. The research team applied a sensitive technique to investigate whether fragments of genetic information in bladder samples could provide reliable signals of cancer.

What the Experimental Test Found

The researchers evaluated the method using samples from 515 people, including individuals with cancer and healthy participants. The results were encouraging: the test identified approximately 95 out of every 100 people with bladder cancer in the study group. The technique also showed potential for recognizing disease at earlier stages. Earlier identification can be valuable because treatment decisions may become more complicated when cancer has progressed.

Beyond detecting the presence of cancer, RNA analysis provided clues about tumor characteristics. The molecular patterns offered information about cancer types and possible recurrence risk. Such details could eventually help clinicians assess individual cases and consider suitable treatment strategies.

How the New Testing Method Could Support Medical Care

One advantage of this approach is sample collection. Obtaining a sample is relatively straightforward and does not require the same procedure as collecting tissue directly from a tumor. This could make repeated testing more convenient if the technology becomes suitable for clinical use.

The possibility of monitoring molecular changes over time is especially interesting. For people receiving treatment, changes in RNA patterns might eventually help researchers assess whether a tumor is responding or showing signs of returning. However, this potential still requires dedicated clinical research.

The scientists also found early indications that the technique might detect signals associated with kidney and prostate cancers. Both areas have connections to the urinary system, making samples from the body's waste-removal process a potentially useful source of biological information. Still, these early observations are not sufficient to establish dependable tests for either condition.

Expert Insight

Stanford University oncologist Maximilian Diehn, who led the research, highlighted why samples collected from the bladder are particularly relevant to cancer investigation. Diehn emphasized that the technology remains at an early stage. He stated: “But absolutely, I think the field needs to investigate it.”

What Must Happen Before Clinical Use

Several questions remain before RNA-based testing can become part of standard medical care. Researchers need to assess its performance in larger and more diverse groups, including people with different cancer stages and other conditions affecting the urinary system.

Testing must also establish how often false-positive and false-negative results occur. A false positive could lead to unnecessary follow-up procedures, while a false negative might create misplaced reassurance. Cost, laboratory requirements, sample handling and consistency between testing facilities will also influence whether the method is practical.

For now, established medical examinations remain essential when bladder cancer is suspected. Symptoms such as visible blood during urination should receive professional medical assessment rather than relying on an experimental test.

RNA analysis in samples collected from the bladder offers a promising direction for cancer research. The experimental method identified around 95 percent of affected participants in its study group and provided additional clues about tumor biology. Its potential applications could extend to monitoring treatment responses and investigating other cancers connected to the urinary system.

Despite the encouraging results, the technique is not yet an established screening method. Larger studies and clinical validation are needed before its reliability and practical benefits can be confirmed. The research nevertheless demonstrates how molecular information from a simple sample could contribute to more informative cancer testing in the future.